Company intelligence / Profile preview

Iroko Holdings

Philadelphia, Pennsylvania, United States

Ownership: Private
Employees: ~180
Development stage: Other

Overview

Iroko's Phase 2 clinical trials of three leading products show potential to compete in the $7 billion global NSAID market. The company develops lower-dose submicron NSAIDs to reduce side effects while maintaining efficacy.

Therapeutic areas: ImmunologyOtherCardiovascularNeurologyRheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

iCeutica (acquired)Liberty Property TrustSynterra Partners

Beyond the preview

Go deeper on Iroko Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iroko Holdings.

Explore the full profile